Key Highlights

● Neuronetics offered a rare upbeat signal on an otherwise cautious tape, with STIM shares ticking higher as the maker of NeuroStar transcranial magnetic stimulation therapy pushes toward profitability.

● Malvern, Pennsylvania-based Neuronetics develops and markets the NeuroStar Advanced Therapy System, a non-invasive, office-based treatment for depression that uses transcranial magnetic stimulation, or TMS.

● The positive tone around STIM aligns with tangible operational progress rather than an unverifiable one-day catalyst.

● For the second quarter of 2026, Neuronetics reported Revenue of about $41.6 million, said adjusted EBITDA turned positive, and noted a narrower net loss, a meaningful shift for a company long focused on reaching sustainable profitability.

Neuronetics, Inc (NASDAQ:STIM) offered a rare upbeat signal on an otherwise cautious tape, with STIM shares ticking higher as the maker of NeuroStar transcranial magnetic stimulation therapy pushes toward profitability. The Nasdaq-listed mental-health device company has spent the past year integrating a major Acquisition and courting psychiatric practices, and recent operational milestones have kept it on investors' September 2026 watchlists. The modest gain contrasts with the pressure weighing on many small-cap medical-device peers.

Company and Latest Development

Malvern, Pennsylvania-based Neuronetics develops and markets the NeuroStar Advanced Therapy System, a non-invasive, office-based treatment for depression that uses transcranial magnetic stimulation, or TMS. The company combined with Greenbrook TMS, adding a national network of treatment centers and transforming Neuronetics from a device supplier into a company with both a product and a direct treatment footprint. In 2026 that integration continued, including the opening of a Greenbrook "National Center of Excellence for Advanced Interventional Psychiatry" in Maryland and, most recently, what the company described as the first-ever integration of TMS with an EHR/EMR system.

What Is Driving Attention Around STIM?

The positive tone around STIM aligns with tangible operational progress rather than an unverifiable one-day catalyst. Neuronetics has reported improving financial metrics and continued commercial initiatives, and the stock's move higher is consistent with a market rewarding evidence of a narrowing path to profitability. As with any small-cap stock, short-term price action can be volatile and is not always tied to fresh news, so the durable story is the company's operational trajectory rather than a single session's gain.

Key Numbers and Company Position

For the second quarter of 2026, Neuronetics reported revenue of about $41.6 million, said adjusted EBITDA turned positive, and noted a narrower net loss, a meaningful shift for a company long focused on reaching sustainable profitability. The company appointed Nir Naor as Chief Financial Officer in July 2026, part of a Leadership refresh as the combined Business scales. Its market Capitalization sits near $232 million, with shares recently around $3. The combination of a positive adjusted-EBITDA quarter and greater revenue scale following the Greenbrook Merger marks tangible progress toward the company's long-stated financial goals, even as the shares trade well below their historic levels.

What Could Come Next?

Upcoming catalysts include future quarterly results that test whether positive adjusted EBITDA can be sustained, further rollout of the EHR/EMR-integrated TMS offering, and continued expansion of the Greenbrook center network. Commercial traction with psychiatric practices, new clinical or reimbursement developments, and updates at investor conferences could all influence sentiment. Demonstrating consistent profitability and cash-flow improvement remains the key development to monitor.

Risks to Watch

Neuronetics still carries integration and execution risk from the Greenbrook combination, including the challenge of running a treatment-center network alongside a device business. The company has historically been unprofitable, and any Reversal in the recent Margin trend could pressure the stock. Competition in TMS and broader interventional psychiatry, reimbursement dynamics, and the capital needs of a small-cap medical-device company add further risk. A relatively low share price can amplify volatility.

Neuronetics Has Several Product Milestones Ahead

Neuronetics enters the latter part of 2026 with genuine operational momentum: a scaled revenue base, a first positive adjusted-EBITDA quarter, and product initiatives that deepen its role in office-based depression care. Investors may be watching whether the company can convert that progress into sustained profitability while integrating Greenbrook and expanding NeuroStar adoption. For a stock that has struggled, evidence of durable financial improvement could remain central to how sentiment around STIM evolves.